ANGPT2 and graft versus host disease: There was no difference in serum Ang2 levels between patients with TMA (median 86 ng/mL, 95% CI, 48–150) and patients with GVHD (median 73 ng/mL, 95% CI, 48–85) (Cohort 1 vs. 2, p = 0.2) at the time of TA-TMA or GVHD diagnosis.